Remove trial restrictions ▶ Start for $1

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Dow
Baxter
AstraZeneca
Merck

Last Updated: May 19, 2022

ENDARI Drug Patent Profile


✉ Email this page to a colleague

« Back to Dashboard

Which patents cover Endari, and what generic alternatives are available?

Endari is a drug marketed by Emmaus Medcl and is included in one NDA.

The generic ingredient in ENDARI is l-glutamine. There are forty-five drug master file entries for this compound. Additional details are available on the l-glutamine profile page.

Summary for ENDARI
US Patents:0
Applicants:1
NDAs:1
Clinical Trials: 3
Formulation / Manufacturing:see details
Drug Prices: Drug price information for ENDARI
What excipients (inactive ingredients) are in ENDARI?ENDARI excipients list
DailyMed Link:ENDARI at DailyMed
Drug patent expirations by year for ENDARI
Drug Prices for ENDARI

See drug prices for ENDARI

DrugPatentWatch® Estimated Generic Entry Opportunity Date for ENDARI
Generic Entry Date for ENDARI*:
Constraining patent/regulatory exclusivity:
TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS 5 YEARS OF AGE AND OLDER.
NDA:
Dosage:
FOR SOLUTION;ORAL

*The generic entry opportunity date is the latter of the last compound-claiming patent and the last regulatory exclusivity protection. Many factors can influence early or later generic entry. This date is provided as a rough estimate of generic entry potential and should not be used as an independent source.

Recent Clinical Trials for ENDARI

Identify potential brand extensions & 505(b)(2) entrants

SponsorPhase
Jun Gong, MDPhase 1
Emmaus Medical, Inc.Phase 1
Emmaus Medical, Inc.Phase 4

See all ENDARI clinical trials

US Patents and Regulatory Information for ENDARI

ENDARI is protected by zero US patents and one FDA Regulatory Exclusivity.

Based on analysis by DrugPatentWatch, the earliest date for a generic version of ENDARI is See Plans and Pricing.

This potential generic entry date is based on TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS 5 YEARS OF AGE AND OLDER..

Generics may enter earlier, or later, based on new patent filings, patent extensions, patent invalidation, early generic licensing, generic entry preferences, and other factors.

FDA Regulatory Exclusivity protecting ENDARI

TO REDUCE THE ACUTE COMPLICATIONS OF SICKLE CELL DISEASE IN ADULT AND PEDIATRIC PATIENTS 5 YEARS OF AGE AND OLDER.
Exclusivity Expiration: See Plans and Pricing

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Emmaus Medcl ENDARI l-glutamine FOR SOLUTION;ORAL 208587-001 Jul 7, 2017 RX Yes No See Plans and Pricing See Plans and Pricing See Plans and Pricing
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Mallinckrodt
Baxter
Harvard Business School
AstraZeneca
Merck

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.